RESUMEN
OBJECTIVE: To investigate the necessity of medication for patients with type â ¢ prostatitis-like symptoms for less than 3 months. METHODS: We enrolled in this study 171 outpatients with type â ¢ prostatitis-like symptoms for less than 3 months in our hospital from November 2016 to October 2017, and randomly divided them into groups A (n = 57), B (n = 57) and C (n = 57). The patients of group A received tamsulosin, levofloxacin and health education, those of group B tamsulosin and health education, and those of group C health education only. Three months later, we evaluated the therapeutic effects according to the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) scores of the patients, 4-point reduction in the total score indicating effectiveness. RESULTS: After 3 months of treatment, the total NIH-CPSI scores of the patients in groups A, B and C were decreased by (9.0 ± 2.9), (8.2 ± 3.4) and (8.6 ± 3.2) points respectively, all indicating effectiveness, the pain scores (4.2 ± 1.8), (4.0 ± 1.9) and (4.2 ± 1.6) points, the urinary symptom scores decreased by decreased by (2.4 ± 1.2), (2.4 ± 1.4) and (2.2 ± 1.2) points, and quality of life scores decreased by (2.4 ± 1.4), (1.9 ± 1.4) and (2.2 ± 1.3) points, none with statistically significant difference among the three groups (P > 0.05). CONCLUSIONS: Health education is proved to have a therapeutic effect on type â ¢ prostatitis-like symptoms similar to that of alpha receptor blockers.
Asunto(s)
Educación del Paciente como Asunto , Prostatitis/tratamiento farmacológico , Prostatitis/terapia , Antagonistas de Receptores Adrenérgicos alfa 1/uso terapéutico , Enfermedad Crónica , Humanos , Levofloxacino/uso terapéutico , Masculino , Estudios Prospectivos , Calidad de Vida , Tamsulosina/uso terapéutico , Estados Unidos , Agentes Urológicos/uso terapéuticoRESUMEN
There is increasing evidence that species diversity is underestimated in the current taxonomy of widespread freshwater fishes. The bagrid species T. albomarginatus s.l. is mainly distributed in the lowlands of South China, as currently identified. A total of 40 localities (including the type locality), which covers most of its known range, were sampled. Molecular phylogenetic analyses based on concatenated mtDNA and nuclear genes recover nine highly supported lineages clustering into eight geographic populations. The integration of molecular evidence, morphological data, and geographic distribution demonstrates the delineation of T. albomarginatus s.l. as eight putative species. Four species, namely, T. albomarginatus, T. lani, T. analis, and T. zhangfei sp. nov. and the T. similis complex are taxonomically recognized herein. Moreover, T. zhangfei sp. nov. comprises two genetically distinct lineages with no morphological and geographical difference. This study also reveals aspects of estimation of divergence time, distribution, and ecological adaption within the T. albomarginatus group. The unraveling of the hidden species diversity of this lowland bagrid fish highlights the need for not only the molecular scrutiny of widely distributed species of South China but also the adjustment of current biodiversity conservation strategies to protect the largely overlooked diversity of fishes from low-elevation rapids.
RESUMEN
OBJECTIVES: To investigate the effects of antihypertensive drugs on the erectile function and number of nNOS-containing nerve fibers in spontaneously hypertensive rats(SHRs). METHODS: Eighteen male SHRs of six-weeks old were randomized into three groups: Vilsartan intervention group, Aldactone intervention group and control group. Vilsartan [30 mg/(kg.d)] and Aldactone [20 mg/(kg.d)] were administered by gavage to respective groups. After twelve weeks treatment, all SHRs were tested for erectile function and then killed for the detection of nNOS-containing nerve fibers by Streptaridin-peroxidase immunohistochemistry techniques (SP method). RESULTS: The erection frequency in Vilsartan group was higher, compared with other two groups(P < 0.05), in which no significant difference was observed (P > 0.05). There was no significant difference in erection rates among these three groups. The number of nNOS-containing nerve fibers in two intervention groups was higher than the control group(P < 0.01), but no significant difference existed between these two groups(P > 0.05). CONCLUSIONS: Vilsartan improves erectile function in SHRs while Aldactone doesn't. The difference can't be explained by the number of nNOS-containing nerve fibers, and it is probably related to the vascular reconstruction induced by angiotensin II receptor antagonists.